Laboratory and clinical aspects of human papillomavirus testing

References

• Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010;401:70–79.
   PubMed Web of Science ®Google Scholar
• Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890–907.
   PubMed Web of Science ®Google Scholar
• Syrjänen S. Current concepts on human papillomavirus infections in children. APMIS 2010;118:494–509.
   PubMed Web of Science ®Google Scholar
• Partridge JM, Koutsky LA. Genital human papillomavirus infection in men. Lancet Infect Dis 2006;6:21–31.
   PubMed Web of Science ®Google Scholar
• Feller L, Wood NH, Khammissa RA, Lemmer J. Human papillomavirus-mediated carcinogenesis and HPV-associated oral and oropharyngeal squamous cell carcinoma. Part 1: human papillomavirus-mediated carcinogenesis. Head Face Med 2010;6:14.
   Google Scholar
• Feller L, Wood NH, Khammissa RA, Lemmer J. Human papillomavirus-mediated carcinogenesis and HPV-associated oral and oropharyngeal squamous cell carcinoma. Part 2: human papillomavirus associated oral and oropharyngeal squamous cell carcinoma. Head Face Med 2010;6:15.
   Google Scholar
• Gallagher TQ, Derkay CS. Recurrent respiratory papillomatosis: update 2008. Curr Opin Otolaryngol Head Neck Surg 2008;16:536–542.
   PubMed Web of Science ®Google Scholar
• Dubina M, Goldenberg G. Viral-associated nonmelanoma skin cancers: a review. Am J Dermatopathol 2009;31:561–573.
   PubMed Web of Science ®Google Scholar
• Feltkamp MC, de Koning MN, Bavinck JN, Ter Schegget J. Betapapillomaviruses: innocent bystanders or causes of skin cancer. J Clin Virol 2008;43:353–360.
   PubMed Web of Science ®Google Scholar
• Handisurya A, Schellenbacher C, Kirnbauer R. Diseases caused by human papillomaviruses (HPV). J Dtsch Dermatol Ges 2009;7:453–466; quiz 466, 467.
   PubMed Web of Science ®Google Scholar
• Pfister H. Chapter 8: Human papillomavirus and skin cancer. J Natl Cancer Inst Monogr 2003;31:52–56.
   PubMedGoogle Scholar
• zur Hausen H. Papillomaviruses in the causation of human cancers – a brief historical account. Virology 2009;384:260–265.
   PubMed Web of Science ®Google Scholar
• Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003;16:1–17.
   PubMed Web of Science ®Google Scholar
• Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006;116:1167–1173.
   PubMed Web of Science ®Google Scholar
• Forslund O, Antonsson A, Nordin P, Stenquist B, Hansson BG. A broad range of human papillomavirus types detected with a general PCR method suitable for analysis of cutaneous tumours and normal skin. J Gen Virol 1999;80:2437–2443.
   PubMed Web of Science ®Google Scholar
• Hazard K, Karlsson A, Andersson K, Ekberg H, Dillner J, Forslund O. Cutaneous human papillomaviruses persist on healthy skin. J Invest Dermatol 2007;127:116–119.
   PubMed Web of Science ®Google Scholar
• Antonsson A, Forslund O, Ekberg H, Sterner G, Hansson BG. The ubiquity and impressive genomic diversity of human skin papillomaviruses suggest a commensalic nature of these viruses. J Virol 2000;74:11636–11641.
   PubMed Web of Science ®Google Scholar
• Mammas IN, Sourvinos G, Spandidos DA. Human papilloma virus (HPV) infection in children and adolescents. Eur J Pediatr 2009;168:267–273.
   PubMed Web of Science ®Google Scholar
• Kirnbauer R, Lenz P, Okun MM. Human Papillomavirus. In: Bolognia J, Jorizzo J, Rapini R, ed. Dermatology, Vol. 1. London: Mosby, 2008:1183–1198.
   Google Scholar
• McLaughlin JS, Shafritz AB. Cutaneous warts. J Hand Surg Am 2011;36:343–344.
   PubMedGoogle Scholar
• Syrjänen KJ. Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland. Scand J Infect Dis Suppl 2009;107:3–32.
   PubMedGoogle Scholar
• Chan PK, Luk AC, Luk TN, Lee KF, Cheung JL, Ho KM, Lo KK. Distribution of human papillomavirus types in anogenital warts of men. J Clin Virol 2009;44:111–114.
   PubMed Web of Science ®Google Scholar
• Oon SF, Winter DC. Perianal condylomas, anal squamous intraepithelial neoplasms and screening: a review of the literature. J Med Screen 2010;17:44–49.
   PubMed Web of Science ®Google Scholar
• Hsueh PR. Human papillomavirus, genital warts, and vaccines. J Microbiol Immunol Infect 2009;42:101–106.
   PubMedGoogle Scholar
• Ghaemmaghami F, Nazari Z, Mehrdad N. Female genital warts. Asian Pac J Cancer Prev 2007;8:339–347.
   PubMedGoogle Scholar
• Larson DA, Derkay CS. Epidemiology of recurrent respiratory papillomatosis. APMIS 2010;118:450–454.
   PubMed Web of Science ®Google Scholar
• Bonagura VR, Hatam LJ, Rosenthal DW, de Voti JA, Lam F, Steinberg BM, Abramson AL. Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11. APMIS 2010;118:455–470.
   PubMed Web of Science ®Google Scholar
• Tasca RA, Clarke RW. Recurrent respiratory papillomatosis. Arch Dis Child 2006;91:689–691.
   PubMed Web of Science ®Google Scholar
• Feller L, Khammissa RA, Wood NH, Malema V, Meyerov R, Lemmer J. Focal epithelial hyperplasia (Heck disease) related to highly active antiretroviral therapy in an HIV-seropositive child. A report of a case, and a review of the literature. SADJ 2010;65:172–175.
   PubMedGoogle Scholar
• Feller L, Khammissa RA, Wood NH, Marnewick JC, Meyerov R, Lemmer J. HPV-associated oral warts. SADJ 2011;66:82–85.
   PubMedGoogle Scholar
• González JV, Gutiérrez RA, Keszler A, Colacino Mdel C, Alonio LV, Teyssie AR, Picconi MA. Human papillomavirus in oral lesions. Medicina (B Aires) 2007;67:363–368.
   PubMed Web of Science ®Google Scholar
• zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342–350.
   PubMed Web of Science ®Google Scholar
• Grulich AE, Jin F, Conway EL, Stein AN, Hocking J. Cancers attributable to human papillomavirus infection. Sex Health 2010;7:244–252.
   PubMed Web of Science ®Google Scholar
• Ramoz N, Rueda LA, Bouadjar B, Montoya LS, Orth G, Favre M. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet 2002;32:579–581.
   PubMed Web of Science ®Google Scholar
• Orth G. Genetics of epidermodysplasia verruciformis: Insights into host defense against papillomaviruses. Semin Immunol 2006;18:362–374.
   PubMed Web of Science ®Google Scholar
• Lazarczyk M, Cassonnet P, Pons C, Jacob Y, Favre M. The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections. Microbiol Mol Biol Rev 2009;73:348–370.
   Web of Science ®Google Scholar
• Sterling JC. Human papillomaviruses and skin cancer. J Clin Virol 2005;32:S67–71.
   PubMed Web of Science ®Google Scholar
• Patel T, Morrison LK, Rady P, Tyring S. Epidermodysplasia verruciformis and susceptibility to HPV. Dis Markers 2010;29:199–206.
   Google Scholar
• Forslund O, Iftner T, Andersson K, Lindelof B, Hradil E, Nordin P, et al; Viraskin Study Group. Cutaneous human papillomaviruses found in sun-exposed skin: Beta-papillomavirus species 2 predominates in squamous cell carcinoma. J Infect Dis 2007;196:876–883.
   PubMed Web of Science ®Google Scholar
• Patel AS, Karagas MR, Perry AE, Nelson HH. Exposure profiles and human papillomavirus infection in skin cancer: an analysis of 25 genus beta-types in a population-based study. J Invest Dermatol 2008;128:2888–2893.
   PubMed Web of Science ®Google Scholar
• Asgari MM, Kiviat NB, Critchlow CW, Stern JE, Argenyi ZB, Raugi GJ, et al. Detection of human papillomavirus DNA in cutaneous squamous cell carcinoma among immunocompetent individuals. J Invest Dermatol 2008;128:1409–1417.
   PubMed Web of Science ®Google Scholar
• Akgül B, Cooke JC, Storey A. HPV-associated skin disease. J Pathol 2006;208:165–175.
   PubMed Web of Science ®Google Scholar
• Bleeker MC, Heideman DA, Snijders PJ, Horenblas S, Dillner J, Meijer CJ. Penile cancer: epidemiology, pathogenesis and prevention. World J Urol 2009;27:141–150.
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24 (Suppl 3):S3/11–25.
   Google Scholar
• Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24 (Suppl 3):S3/1–10.
   Google Scholar
• Chao A, Chen TC, Hsueh C, Huang CC, Yang JE, Hsueh S, et al. Human papillomavirus in vaginal intraepithelial neoplasia. Int J Cancer 2012;131:E259–E268.
   Web of Science ®Google Scholar
• Hildesheim A, Han CL, Brinton LA, Kurman RJ, Schiller JT. Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancer: results from a seroepidemiological case-control study. Obstet Gynecol 1997;90:748–754.
   PubMed Web of Science ®Google Scholar
• Tumours of the vulva. In: Tavassoli FA, Devilee P, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003: 313–333.
   Google Scholar
• Junge J, Poulsen H, Horn T, Hørding U, Lundvall F. Human papillomavirus (HPV) in vulvar dysplasia and carcinoma in situ. APMIS 1995;103:501–510.
   PubMed Web of Science ®Google Scholar
• Alonso I, Fusté V, del Pino M, Castillo P, Torné A, Fusté P, et al. Does human papillomavirus infection imply a different prognosis in vulvar squamous cell carcinoma? Gynecol Oncol 2011;122:509–514.
   PubMed Web of Science ®Google Scholar
• Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004;101:270–280.
   PubMed Web of Science ®Google Scholar
• Dietz CA, Nyberg CR. Genital, oral, and anal human papillomavirus infection in men who have sex with men. J Am Osteopath Assoc 2011;111(3 Suppl 2):S19–S25.
   Google Scholar
• Palefsky J. Can HPV vaccination help to prevent anal cancer? Lancet Infect Dis 2010;10:815–816.
   PubMed Web of Science ®Google Scholar
• Smith PG, Kinlen LJ, White GC, Adelstein AM, Fox AJ. Mortality of wives of men dying with cancer of the penis. Br J Cancer 1980;41:422–428.
   PubMed Web of Science ®Google Scholar
• Picconi MA, Eiján AM, Distéfano AL, Pueyo S, Alonio LV, Gorostidi ST, et al. Human papillomavirus (HPV) DNA in penile carcinomas in Argentina: analysis of primary tumors and lymph nodes. J Med Virol 2000;61:65–69.
   PubMed Web of Science ®Google Scholar
• Palefsky JM. Human papillomavirus-related disease in men: not just a women’s issue. J Adolesc Health 2010;46(4 Suppl):S12–S19.
   Web of Science ®Google Scholar
• Anic GM, Giuliano AR. Genital HPV infection and related lesions in men. Prev Med 2011;53 (Suppl 1):S36–S41.
   Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
   PubMed Web of Science ®Google Scholar
• WHO. 2008–2013 Action Plan for the Global Strategy for the Prevention and Control of Noncommunicable Diseases. Geneva, Switzerland: World Health Organization 2008;1–42.
   Google Scholar
• Yang BH, Bray FI, Parkin DM, Sellors JW, Zhang ZF. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer 2004;109:418–424.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, Ferlay J. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22:2675–2686.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893–2917.
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29:4294–4301.
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26:612–619.
   PubMed Web of Science ®Google Scholar
• Allen CT, Lewis JS Jr, El-Mofty SK, Haughey BH, Nussenbaum B. Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope 2010;120:1756–1772.
   PubMed Web of Science ®Google Scholar
• Marur S, D’Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010;11:781–789.
   PubMed Web of Science ®Google Scholar
• Syrjänen S, Lodi G, von Bültzingslöwen I, Aliko A, Arduino P, Campisi G, et al. Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review. Oral Dis 2011;17 (Suppl 1):58–72.
   PubMedGoogle Scholar
• Toner M, O’Regan EM. Head and neck squamous cell carcinoma in the young: a spectrum or a distinct group? Part 1. Head Neck Pathol 2009;3:246–248.
   PubMedGoogle Scholar
• Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 2011;11:9–22.
   PubMed Web of Science ®Google Scholar
• Howley PM, Lowy DR. Papillomavirus. In: Knipe DM, Howley PM, et al., eds: Fields Virology, Vol. 2. 5th ed. Philadelphia: Lippincott Williams and Wilkins, 2007: 2299–2354.
   Google Scholar
• Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 2004;68:362–372.
   PubMed Web of Science ®Google Scholar
• Doorbar J. The papillomavirus life cycle. J Clin Virol 2005;32 (Suppl 1):S7–S15.
   PubMed Web of Science ®Google Scholar
• Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992;89:12180–12184.
   PubMed Web of Science ®Google Scholar
• Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991;185:251–257.
   PubMed Web of Science ®Google Scholar
• Chen J, Ni G, Liu XS. Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: immunological problems and future directions. Cell Immunol 2011;269:5–9.
   PubMed Web of Science ®Google Scholar
• Villa LL. HPV prophylactic vaccination: The first years and what to expect from now. Cancer Lett 2011;305:106–112.
   PubMed Web of Science ®Google Scholar
• Frazer IH. Cervical cancer vaccine development. Sex Health 2010;7:230–234.
   PubMed Web of Science ®Google Scholar
• Tumban E, Peabody J, Peabody DS, Chackerian B. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS One 2011;6:e23310.
   PubMed Web of Science ®Google Scholar
• Conway MJ, Cruz L, Alam S, Christensen ND, Meyers C. Cross-neutralization potential of native human papillomavirus N-terminal L2 epitopes. PLoS One 2011;6:e16405.
   Web of Science ®Google Scholar
• Caldeira Jdo C, Medford A, Kines RC, Lino CA, Schiller JT, Chackerian B, Peabody DS. Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine 2010;28:4384–4393.
   PubMed Web of Science ®Google Scholar
• Stanley M. Prospects for new human papillomavirus vaccines. Curr Opin Infect Dis 2010;23:70–75.
   PubMed Web of Science ®Google Scholar
• Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248:76–79.
   PubMed Web of Science ®Google Scholar
• Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993;75:495–505.
   PubMed Web of Science ®Google Scholar
• White AE, Livanos EM, Tlsty TD. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev 1994;8:666–677.
   PubMed Web of Science ®Google Scholar
• Havre PA, Yuan J, Hedrick L, Cho KR, Glazer PM. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res 1995;55:4420–4424.
   PubMed Web of Science ®Google Scholar
• Kessis TD, Connolly DC, Hedrick L, Cho KR. Expression of HPV16 E6 or E7 increases integration of foreign DNA. Oncogene 1996;13:427–431.
   PubMed Web of Science ®Google Scholar
• Ronco LV, Karpova AY, Vidal M, Howley PM. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998;12:2061–2072.
   PubMed Web of Science ®Google Scholar
• Thomas M, Banks L. Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 1998;17:2943–2954.
   PubMed Web of Science ®Google Scholar
• Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996;380:79–82.
   PubMed Web of Science ®Google Scholar
• Reznikoff CA, Yeager TR, Belair CD, Savelieva E, Puthenveettil JA, Stadler WM. Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res 1996;56:2886–2890.
   PubMed Web of Science ®Google Scholar
• Dyson N, Howley PM, Münger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934–937.
   PubMed Web of Science ®Google Scholar
• Dyson N, Guida P, Münger K, Harlow E. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J Virol 1992;66:6893–6902.
   PubMed Web of Science ®Google Scholar
• Arroyo M, Bagchi S, Raychaudhuri P. Association of the human papillomavirus type 16 E7 protein with the S-phase-specific E2F-cyclin A complex. Mol Cell Biol 1993;13:6537–6546.
   PubMed Web of Science ®Google Scholar
• Funk JO, Waga S, Harry JB, Espling E, Stillman B, Galloway DA. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 1997;11:2090–2100.
   PubMed Web of Science ®Google Scholar
• Smotkin D, Wettstein FO. Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein. Proc Natl Acad Sci USA 1986;83:4680–4684.
   PubMed Web of Science ®Google Scholar
• Chang JL, Tsao YP, Liu DW, Huang SJ, Lee WH, Chen SL. The expression of HPV-16 E5 protein in squamous neoplastic changes in the uterine cervix. J Biomed Sci. 2001;8:206–213.
   PubMed Web of Science ®Google Scholar
• Maufort JP, Shai A, Pitot HC, Lambert PF. A role for HPV16 E5 in cervical carcinogenesis. Cancer Res 2010;70:2924–2931.
   PubMed Web of Science ®Google Scholar
• Venuti A, Paolini F, Nasir L, Corteggio A, Roperto S, Campo MS, Borzacchiello G. Papillomavirus E5: the smallest oncoprotein with many functions. Mol Cancer 2011;10:140.
   PubMed Web of Science ®Google Scholar
• Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006;110:525–541.
   PubMed Web of Science ®Google Scholar
• Romanczuk H, Thierry F, Howley PM. Mutational analysis of cis elements involved in E2 modulation of human papillomavirus type 16 P97 and type 18 P105 promoters. J Virol 1990;64:2849–2859.
   PubMed Web of Science ®Google Scholar
• Zheng ZM, Baker CC. Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci 2006;11:2286–2302.
   PubMed Web of Science ®Google Scholar
• Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006;208:152–164.
   PubMed Web of Science ®Google Scholar
• de Villiers EM, Bernard HU, Broker T, Delius H, zur Hausen H. Family Papillomaviridae. In: Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA, eds. Virus Taxonomy. Eighth Report of the International Committee on Taxonomy of Viruses. San Diego: Elsevier Academic Press, 2005:239–255.
   Google Scholar
• Family Papillomaviridae. In: Van Regenmortel MH, Fauquet CM, Bishop DH, Carstens EB, Estes MK, Lemon SM, et al., eds. Virus Taxonomy. Seventh Report of the International Committee for the Taxonomy of Viruses. San Diego: Academic Press, 2000:247–251.
   Google Scholar
• de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004;324:17–27.
   PubMed Web of Science ®Google Scholar
• Calleja-Macias IE, Villa LL, Prado JC, Kalantari M, Allan B, Williamson AL, et al. Worldwide genomic diversity of the high-risk human papillomavirus types 31, 35, 52, and 58, four close relatives of human papillomavirus type 16. J Virol 2005;79:13630–13640.
   PubMed Web of Science ®Google Scholar
• Chan PK, Luk AC, Park JS, Smith-McCune KK, Palefsky JM, Konno R, et al. Identification of human papillomavirus type 58 lineages and the distribution worldwide. J Infect Dis 2011;203:1565–1573.
   PubMed Web of Science ®Google Scholar
• Chen Z, Schiffman M, Herrero R, Desalle R, Anastos K, Segondy M, et al. Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. PLoS One 2011;6:e20183.
   Web of Science ®Google Scholar
• Chen Z, DeSalle R, Schiffman M, Herrero R, Burk RD. Evolutionary dynamics of variant genomes of human papillomavirus types 18, 45, and 97. J Virol 2009;83:1443–1455.
   PubMed Web of Science ®Google Scholar
• Prado JC, Calleja-Macias IE, Bernard HU, Kalantari M, Macay SA, Allan B, et al. Worldwide genomic diversity of the human papillomaviruses-53, 56, and 66, a group of high-risk HPVs unrelated to HPV-16 and HPV-18. Virology 2005;340:95–104.
   PubMed Web of Science ®Google Scholar
• Raiol T, Wyant PS, de Amorim RM, Cerqueira DM, Milanezi NG, Brígido Mde M, et al. Genetic variability and phylogeny of the high-risk HPV-31, -33, -35, -52, and -58 in central Brazil. J Med Virol 2009;81:685–692.
   PubMed Web of Science ®Google Scholar
• Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al.; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518–527.
   PubMed Web of Science ®Google Scholar
• Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005;337:76–84.
   PubMed Web of Science ®Google Scholar
• Herrero R. Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J Infect Dis 2009;199:919–922.
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, et al.; for the HPV PATRICIA Study Group. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:100–110.
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, et al; for the HPV PATRICIA Study Group. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:100–110.
   PubMed Web of Science ®Google Scholar
• Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis 2009;199:926–935.
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 years. J Infect Dis 2009;199:936–944.
   PubMed Web of Science ®Google Scholar
• Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009;4:8.
   PubMedGoogle Scholar
• Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F; WHO International Agency for Research on Cancery. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005;6:204.
   Web of Science ®Google Scholar
• Chow LT, Broker TR. In vitro experimental systems for HPV: epithelial raft cultures for investigations of viral reproduction and pathogenesis and for genetic analyses of viral proteins and regulatory sequences. Clin Dermatol 1997;15:217–227.
   PubMed Web of Science ®Google Scholar
• Dollard SC, Wilson JL, Demeter LM, Bonnez W, Reichman RC, Broker TR, Chow LT. Production of human papillomavirus and modulation of the infectious program in epithelial raft cultures. OFF. Genes Dev 1992;6:1131–1142.
   PubMed Web of Science ®Google Scholar
• Meyers C, Frattini MG, Hudson JB, Laimins LA. Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science 1992;257:971–973.
   PubMed Web of Science ®Google Scholar
• Stanley M. Immune responses to human papillomavirus. Vaccine 2006;24 (Suppl 1):S16–S22.
   PubMed Web of Science ®Google Scholar
• Frazer IH. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology 2009;384:410–414.
   PubMed Web of Science ®Google Scholar
• Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004;4:211–222.
   PubMed Web of Science ®Google Scholar
• Le Bon A, Tough DF. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 2002;14:432–436.
   PubMed Web of Science ®Google Scholar
• Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005;23:307–336.
   PubMed Web of Science ®Google Scholar
• Chang YE, Laimins LA. Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J Virol 2000;74:4174–4182.
   PubMed Web of Science ®Google Scholar
• Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, Woodworth CD. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J Virol 2001;75:4283–4296.
   PubMed Web of Science ®Google Scholar
• Kobayashi A, Greenblatt RM, Anastos K, Minkoff H, Massad LS, Young M, et al. Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res 2004;64:6766–6774.
   PubMed Web of Science ®Google Scholar
• Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 1994;86:494–499.
   PubMed Web of Science ®Google Scholar
• Wikström A, van Doornum GJ, Quint WG, Schiller JT, Dillner J. Identification of human papillomavirus seroconversions. J Gen Virol 1995;76:529–539.
   PubMed Web of Science ®Google Scholar
• Carter JJ, Wipf GC, Hagensee ME, McKnight B, Habel LA, Lee SK, et al. Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts. J Infect Dis 1995;172:11–18.
   PubMed Web of Science ®Google Scholar
• Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000;181:1911–1919.
   PubMed Web of Science ®Google Scholar
• Heideman DA, Hesselink AT, Berkhof J, van Kemenade F, Melchers WJ, Daalmeijer NF, et al. Clinical validation of the Cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol 2011;49:3983–3985.
   PubMed Web of Science ®Google Scholar
• Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009;124:516–520.
   PubMed Web of Science ®Google Scholar
• Meijer CJ, Berkhof H, Heideman DA, Hesselink AT, Snijders PJ. Validation of high-risk HPV tests for primary cervical screening. J Clin Virol 2009;46(Suppl 3):S1–S4.
   Google Scholar
• Lörincz A. Hybrid capture method for detection of human papillomavirus DNA in clinical specimens: a tool for clinical management of equivocal Pap smears and for population screening. J Obstet Gynaecol Res 1996;22:629–36.
   PubMedGoogle Scholar
• Peyton CL, Schiffman M, Lorincz AT, Hunt WC, Mielzynska I, Bratti C, et al. Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. Clin Microbiol 1998;36:3248–3254.
   Google Scholar
• Castle PE, Schiffman M, Burk RD, Wacholder S, Hildesheim A, Herrero R, et al. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev 2002;11:1394–1399.
   PubMed Web of Science ®Google Scholar
• Ting Y, Manos M. Detection and typing of genital human papillomaviruses. In: Innis M, Gelfand D, Sninsky J, White T, eds. PCR Protocols: A Guide to Methods and Applications. San Diego: Academic Press, 1990:356–366.
   Google Scholar
• Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlée F, Hildesheim A, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357–361.
   PubMed Web of Science ®Google Scholar
• Estrade C, Menoud PA, Nardelli-Haefliger D, Sahli R. Validation of a low-cost human papillomavirus genotyping assay based on PGMY PCR and reverse blotting hybridization with reusable membranes. J Clin Microbiol 2011;49:3474–3481.
   PubMed Web of Science ®Google Scholar
• de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995;76:1057–1062.
   PubMed Web of Science ®Google Scholar
• Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997;35:791–795.
   PubMed Web of Science ®Google Scholar
• Chan PK, Cheung TH, Tam AO, Lo KW, Yim SF, Yu MM, et al. Biases in human papillomavirus genotype prevalence assessment associated with commonly used consensus primers. Int J Cancer 2006;118:243–245.
   PubMed Web of Science ®Google Scholar
• Kleter B, van Doorn LJ, ter Schegget J, Schrauwen L, van Krimpen K, Burger M, et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol 1998;153:1731–1739.
   PubMed Web of Science ®Google Scholar
• Jeney C, Takács T, Sebe A, Schaff Z. Detection and typing of 46 genital human papillomaviruses by the L1F/L1R primer system based multiplex PCR and hybridization. J Virol Methods 2007;140:32–42.
   PubMed Web of Science ®Google Scholar
• Bernard HU, Chan SY, Manos MM, Ong CK, Villa LL, Delius H, et al. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis 1994;170:1077–1085.
   PubMed Web of Science ®Google Scholar
• Chan PK, Li WH, Chan MY, Ma WL, Cheung JL, Cheng AF. High prevalence of human papillomavirus type 58 in Chinese women with cervical cancer and precancerous lesions. J Med Virol 1999;59:232–238.
   PubMed Web of Science ®Google Scholar
• Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12–19.
   PubMed Web of Science ®Google Scholar
• Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010;10:550–560.
   PubMed Web of Science ®Google Scholar
• McLaughlin-Drubin ME, Münger K. Oncogenic activities of human papillomaviruses. Virus Res 2009;143:195–208.
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen JJ, Gao Q, Dalal S, Hong Y, Mansur CP, et al. Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. J Virol 1999;73:7297–7307.
   PubMed Web of Science ®Google Scholar
• Pim D, Banks L. Interaction of viral oncoproteins with cellular target molecules: infection with high-risk vs low-risk human papillomaviruses. APMIS 2010;118:471–493.
   PubMed Web of Science ®Google Scholar
• Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B, Tommasino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes 2010;40:1–13.
   PubMed Web of Science ®Google Scholar
• Ganguly N, Parihar SP. Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis. J Biosci 2009;34:113–123.
   PubMed Web of Science ®Google Scholar
• Howie HL, Katzenellenbogen RA, Galloway DA. Papillomavirus E6 proteins. Virology 2009;384:324–334.
   PubMed Web of Science ®Google Scholar
• Gnanamony M, Peedicayil A, Subhashini J, Ram TS, Rajasekar A, Gravitt P, Abraham P. Detection and quantitation of HPV 16 and 18 in plasma of Indian women with cervical cancer. Gynecol Oncol 2010;116:447–451.
   PubMed Web of Science ®Google Scholar
• Flores-Munguia R, Siegel E, Klimecki WT, Giuliano AR. Performance assessment of eight high-throughput PCR assays for viral load quantitation of oncogenic HPV types. J Mol Diagn 2004;6:115–124.
   PubMed Web of Science ®Google Scholar
• Chow LT, Broker TR, Steinberg BM. The natural history of human papillomavirus infections of the mucosal epithelia. APMIS 2010;118:422–449.
   PubMed Web of Science ®Google Scholar
• Cheng S, Schmidt-Grimminger DC, Murant T, Broker TR, Chow LT. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev 1995;9:2335–2349.
   PubMed Web of Science ®Google Scholar
• Chow LT, Broker TR. Mechanisms and regulation of papillomavirus DNA replication. In: Campo MS, ed. Recent Advances in Papillomavirus Research. Norwich, UK: Caister Academic Press, 2006:53–71.
   Google Scholar
• Sotlar K, Selinka HC, Menton M, Kandolf R, Bültmann B. Detection of human papillomavirus type 16 E6/E7 oncogene transcripts in dysplastic and nondysplastic cervical scrapes by nested RT-PCR. Gynecol Oncol 1998;69:114–121.
   PubMed Web of Science ®Google Scholar
• Sotlar K, Stubner A, Diemer D, Menton S, Menton M, Dietz K, et al. Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction. J Med Virol 2004;74:107–116.
   PubMed Web of Science ®Google Scholar
• Lie AK, Risberg B, Borge B, Sandstad B, Delabie J, Rimala R, et al. DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol Oncol 2005;97:908–915.
   PubMed Web of Science ®Google Scholar
• Andersson S, Hansson B, Norman I, Gaberi V, Mints M, Hjerpe A, et al. Expression of E6/E7 mRNA from ‘high risk’ human papillomavirus in relation to CIN grade, viral load and p16INK4a. Int J Oncol 2006;29:705–711.
   PubMed Web of Science ®Google Scholar
• Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P, et al. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer. J Clin Microbiol 2010;48:2779–2785.
   PubMed Web of Science ®Google Scholar
• Castle PE, Dockter J, Giachetti C, Garcia FA, McCormick MK, Mitchell AL, et al. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin Cancer Res 2007;13:2599–2605.
   PubMed Web of Science ®Google Scholar
• Cattani P, Zannoni GF, Ricci C, D’Onghia S, Trivellizzi IN, Di Franco A, et al. Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. J Clin Microbiol 2009;47:3895–3901.
   PubMed Web of Science ®Google Scholar
• Dockter J, Schroder A, Hill C, Guzenski L, Monsonego J, Giachetti C. Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. J Clin Virol 2009;45 (Suppl 1):S55–S61.
   Google Scholar
• Halfon P, Benmoura D, Agostini A, Khiri H, Martineau A, Penaranda G, Blanc B. Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ HPV assay. J Clin Virol 2010;47:177–181.
   PubMed Web of Science ®Google Scholar
• Burger EA, Kornør H, Klemp M, Lauvrak V, Kristiansen IS. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. Gynecol Oncol 2011;120:430–438.
   PubMed Web of Science ®Google Scholar
• Dreier K, Scheiden R, Lener B, Ehehalt D, Pircher H, Müller-Holzner E, et al. Subcellular localization of the human papillomavirus 16 E7 oncoprotein in CaSki cells and its detection in cervical adenocarcinoma and adenocarcinoma in situ. Virology 2011;409:54–68.
   PubMed Web of Science ®Google Scholar
• Ressler S, Scheiden R, Dreier K, Laich A, Müller-Holzner E, Pircher H, et al. High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma. Clin Cancer Res 2007;13:7067–7072.
   PubMed Web of Science ®Google Scholar
• Franco EL, Duarte-Franco E, Rohan TE. Evidence-based policy recommendations on cancer screening and prevention. Cancer Detect Prev 2002;26:350–361.
   PubMedGoogle Scholar
• Sasieni P, Adams J. Effect of screening on cervical cancer mortality in England and Wales: analysis of trends with an age period cohort model. BMJ 1999;318:1244–1245.
   PubMed Web of Science ®Google Scholar
• van der Aa MA, Pukkala E, Coebergh JW, Anttila A, Siesling S. Mass screening programmes and trends in cervical cancer in Finland and the Netherlands. Int J Cancer 2008;122:1854–1858.
   PubMed Web of Science ®Google Scholar
• Bulkmans NW, Rozendaal L, Voorhorst FJ, Snijders PJ, Meijer CJ. Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening. Br J Cancer 2005;92:1800–1802.
   PubMed Web of Science ®Google Scholar
• Sasieni PD, Cuzick J, Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer 1996;73:1001–1005.
   PubMed Web of Science ®Google Scholar
• WHO/ICO Information Centre on HPV and Cervical Cancer. HPV and cervical cancer in the 2007 report. Vaccine 2007;25:C1–C230.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095–1101.
   PubMed Web of Science ®Google Scholar
• Poljak M, Kocjan BJ. Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Rev Anti Infect Ther 2010;8:1139–1162.
   PubMed Web of Science ®Google Scholar
• Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589–1597.
   PubMed Web of Science ®Google Scholar
• Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764–1772.
   PubMed Web of Science ®Google Scholar
• Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al.; New Technologies for Cervical Cancer screening (NTCC) Working Group. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010;11:249–257.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008;26 (Suppl 10):K29–K41.
   Google Scholar
• Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol 2007;104:232–246.
   PubMed Web of Science ®Google Scholar
• Cuschieri KS, Cubie HA. The role of human papillomavirus testing in cervical screening. J Clin Virol 2005;32 (Suppl 1):S34–S42.
   Google Scholar
• Wright TC Jr. HPV DNA testing for cervical cancer screening. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95 (Suppl 1):S239–S246.
   Google Scholar
• Dehn D, Torkko KC, Shroyer KR. Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma. Cancer 2007;111:1–14.
   PubMed Web of Science ®Google Scholar
• Bigras G, de Marval F. The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women. Br J Cancer 2005;93:575–581.
   PubMed Web of Science ®Google Scholar
• Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, et al.; New Technologies for Cervical Cancer Working Group. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006;98:765–774.
   PubMed Web of Science ®Google Scholar
• Belinson J, Qiao YL, Pretorius R, Zhang WH, Elson P, Li L, et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol 2001;83:439–444.
   PubMed Web of Science ®Google Scholar
• Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000;92:464–474.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003;362:1871–1876.
   PubMed Web of Science ®Google Scholar
• Petry KU, Menton S, Menton M, van Loenen-Frosch F, de Carvalho Gomes H, Holz B, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003;88:1570–1577.
   PubMed Web of Science ®Google Scholar
• Wright TC Jr, Denny L, Kuhn L, Pollack A, Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000;283:81–86.
   PubMed Web of Science ®Google Scholar
• Chan PK, Chang AR, Yu MY, Li WH, Chan MY, Yeung AC, Cheung TH, et al. Age distribution of human papillomavirus infection and cervical neoplasia reflects caveats of cervical screening policies. Int J Cancer 2010;126:297–301.
   PubMed Web of Science ®Google Scholar
• Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahé C, Wright TC; Alliance for Cervical Cancer Prevention Cost Working Group. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 2005;353:2158–2168.
   PubMed Web of Science ®Google Scholar
• Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62:147–172.
   PubMed Web of Science ®Google Scholar
• de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al.; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11:1048–1056.
   PubMed Web of Science ®Google Scholar
• Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011;128:927–935.
   PubMed Web of Science ®Google Scholar
• Insinga RP, Liaw KL, Johnson LG, Madeleine MM. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008;17:1611–1622.
   PubMed Web of Science ®Google Scholar
• Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63–73.
   PubMed Web of Science ®Google Scholar
• Chan PK, Cheung TH, Li WH, Yu MY, Chan MY, Yim SF, et al. Attribution of human papillomavirus types to cervical intraepithelial neoplasia and invasive cancers in Southern China. Int J Cancer 2012;131:692–705.
   PubMed Web of Science ®Google Scholar
• Yip YC, Ngai KL, Vong HT, Tzang LC, Ji S, Yang M, Chan PK. Prevalence and genotype distribution of cervical human papillomavirus infection in Macao. J Med Virol 2010;82:1724–1729.
   PubMed Web of Science ®Google Scholar
• Hlaing T, Yip YC, Ngai KL, Vong HT, Wong SI, Ho WC, et al. Distribution of human papillomavirus genotypes among cervical intraepithelial neoplasia and invasive cancers in Macao. J Med Virol 2010;82:1600–1605.
   PubMed Web of Science ®Google Scholar
• Chan PK, Ho WC, Yu MY, Pong WM, Chan AC, Chan AK, Cheung et al. Distribution of human papillomavirus types in cervical cancers in Hong Kong: current situation and changes over the last decades. Int J Cancer 2009;125:1671–1677.
   PubMed Web of Science ®Google Scholar
• Chan PK, Lam CW, Cheung TH, Li WW, Lo KW, Chan MY, et al. Association of human papillomavirus type 58 variant with the risk of cervical cancer. J Natl Cancer Inst 2002;94:1249–1253.
   PubMed Web of Science ®Google Scholar
• Huang S, Afonina I, Miller BA, Beckmann AM. Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women. Int J Cancer 1997;70:408–411.
   PubMed Web of Science ®Google Scholar
• Wu EQ, Zhang GN, Yu XH, Ren Y, Fan Y, Wu YG, et al. Evaluation of high-risk human papillomaviruses type distribution in cervical cancer in Sichuan province of China. BMC Cancer 2008;8:202.
   Web of Science ®Google Scholar
• Ding DC, Hsu HC, Huang RL, Lai HC, Lin CY, Yu MH, Chu TY. Type-specific distribution of HPV along the full spectrum of cervical carcinogenesis in Taiwan: an indication of viral oncogenic potential. Eur J Obstet Gynecol Reprod Biol 2008;140:245–251.
   PubMed Web of Science ®Google Scholar
• Asato T, Maehama T, Nagai Y, Kanazawa K, Uezato H, Kariya K. A large case-control study of cervical cancer risk associated with human papillomavirus infection in Japan, by nucleotide sequencing-based genotyping. J Infect Dis 2004;189:1829–1832.
   PubMed Web of Science ®Google Scholar
• Castle PE, Rodríguez AC, Burk RD, Herrero R, Wacholder S, Alfaro M, et al.; Proyecto Epidemiológico Guanacaste (PEG) Group. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ 2009;339:b2569.
   Google Scholar
• Wentzensen N, von Knebel Doeberitz M. Biomarkers in cervical cancer screening. Dis Markers 2007;23:315–330.
   PubMed Web of Science ®Google Scholar
• Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2008;17:2536–2545.
   PubMed Web of Science ®Google Scholar
• Molden T, Kraus I, Karlsen F, Skomedal H, Nygård JF, Hagmar B. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev 2005;14:367–372.
   PubMed Web of Science ®Google Scholar
• Gupta N, Srinivasan R, Rajwanshi A. Functional biomarkers in cervical precancer: an overview. Diagn Cytopathol 2010;38:618–623.
   PubMed Web of Science ®Google Scholar
• Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, De Marco L, et al.; New Technologies for Cervival Cancer Screening (NTCC) Working Group. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2008;9:937–945.
   PubMed Web of Science ®Google Scholar
• Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92:276–284.
   PubMed Web of Science ®Google Scholar
• Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998;153:1741–1748.
   PubMed Web of Science ®Google Scholar
• Keating JT, Cviko A, Riethdorf S, Riethdorf L, Quade BJ, Sun D, et al. Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol 2001;25:884–891.
   PubMed Web of Science ®Google Scholar
• Nakao Y, Yang X, Yokoyama M, Ferenczy A, Tang SC, Pater MM, Pater A. Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. Br J Cancer 1997;75:1410–1416.
   PubMed Web of Science ®Google Scholar
• Petry KU, Schmidt D, Scherbring S, Luyten A, Reinecke-Lüthge A, Bergeron C, et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 dual-stained cytology. Gynecol Oncol 2011;121:505–509.
   PubMed Web of Science ®Google Scholar
• Hudelist G, Manavi M, Pischinger KI, Watkins-Riedel T, Singer CF, Kubista E, Czerwenka KF. Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. Gynecol Oncol 2004;92:873–880.
   PubMed Web of Science ®Google Scholar
• Wentzensen N, Vinokurova S, von Knebel Doeberitz M. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res 2004;64:3878–3884.
   PubMed Web of Science ®Google Scholar
• Kulmala SM, Syrjänen SM, Gyllensten UB, Shabalova IP, Petrovichev N, Tosi P, et al. Early integration of high copy HPV16 detectable in women with normal and low grade cervical cytology and histology. J Clin Pathol 2006;59:513–517.
   PubMed Web of Science ®Google Scholar
• Gallo G, Bibbo M, Bagella L, Zamparelli A, Sanseverino F, Giovagnoli MR, et al. Study of viral integration of HPV-16 in young patients with LSIL. J Clin Pathol 2003;56:532–536.
   PubMed Web of Science ®Google Scholar
• Cheung JL, Cheung TH, Tang JW, Chan PK. Increase of integration events and infection loads of human papillomavirus type 52 with lesion severity from low-grade cervical lesion to invasive cancer. J Clin Microbiol 2008;46:1356–1362.
   PubMed Web of Science ®Google Scholar
• Cheung JL, Cheung TH, Ng CW, Yu MY, Wong MC, Siu SS, et al. Analysis of human papillomavirus type 18 load and integration status from low-grade cervical lesion to invasive cervical cancer. J Clin Microbiol 2009;47:287–293.
   PubMed Web of Science ®Google Scholar
• Vinokurova S, Wentzensen N, Kraus I, Klaes R, Driesch C, Melsheimer P, et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 2008;68:307–313.
   PubMed Web of Science ®Google Scholar
• Arias-Pulido H, Peyton CL, Joste NE, Vargas H, Wheeler CM. Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. J Clin Microbiol 2006;44:1755–1762.
   PubMed Web of Science ®Google Scholar
• Ho CM, Chien TY, Huang SH, Lee BH, Chang SF. Integrated human papillomavirus types 52 and 58 are infrequently found in cervical cancer, and high viral loads predict risk of cervical cancer. Gynecol Oncol 2006;102:54–60.
   PubMed Web of Science ®Google Scholar
• Cheung JL, Lo KW, Cheung TH, Tang JW, Chan PK. Viral load, E2 gene disruption status, and lineage of human papillomavirus type 16 infection in cervical neoplasia. J Infect Dis 2006;194:1706–1712.
   PubMed Web of Science ®Google Scholar
• Chan PK, Cheung JL, Cheung TH, Lo KW, Yim SF, Siu SS, Tang JW. Profile of viral load, integration, and E2 gene disruption of HPV58 in normal cervix and cervical neoplasia. J Infect Dis 2007;196:868–875.
   PubMed Web of Science ®Google Scholar
• Bhattacharjee B, Sengupta S. CpG methylation of HPV 16 LCR at E2 binding site proximal to P97 is associated with cervical cancer in presence of intact E2. Virology 2006;354:280–285.
   PubMed Web of Science ®Google Scholar
• Badal V, Chuang LS, Tan EH, Badal S, Villa LL, Wheeler CM, et al. CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression. J Virol 2003;77:6227–6234.
   PubMed Web of Science ®Google Scholar
• Ding DC, Chiang MH, Lai HC, Hsiung CA, Hsieh CY, Chu TY. Methylation of the long control region of HPV16 is related to the severity of cervical neoplasia. Eur J Obstet Gynecol Reprod Biol 2009;147:215–220.
   PubMed Web of Science ®Google Scholar
• Kalantari M, Calleja-Macias IE, Tewari D, Hagmar B, Lie K, Barrera-Saldana HA, et al. Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia. J Virol 2004;78:12762–12772.
   PubMed Web of Science ®Google Scholar
• Kim K, Garner-Hamrick PA, Fisher C, Lee D, Lambert PF. Methylation patterns of papillomavirus DNA, its influence on E2 function, and implications in viral infection. J Virol 2003;77:12450–12459.
   PubMed Web of Science ®Google Scholar
• Mirabello L, Sun C, Ghosh A, Rodriguez AC, Schiffman M, Wentzensen N, et al. Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a costarican population. J Natl Cancer Inst. 2012;104:556–565.
   PubMedGoogle Scholar
• Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003;95:46–52.
   PubMedGoogle Scholar
• Kjaer S, Høgdall E, Frederiksen K, Munk C, van den Brule A, Svare E, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 2006;66:10630–10636.
   PubMed Web of Science ®Google Scholar
• Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al.; Joint European Cohort Study. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754.
   PubMedGoogle Scholar
• Wright TC Jr, Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004;103:304–309.
   PubMed Web of Science ®Google Scholar
• Cervical cytology screening. ACOG Practice Bulletin no. 109. Obstet Gynecol 2009;114:1409–20.
   PubMedGoogle Scholar
• Kinney W, Stoler MH, Castle PE. Special commentary: patient safety and the next generation of HPV DNA tests. Am J Clin Pathol 2010;134:193–199.
   PubMed Web of Science ®Google Scholar
• Kjær SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010;102:1478–1488.
   PubMedGoogle Scholar
• Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D; 2006 ASCCP-Sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 2007;11:201–222.
   PubMedGoogle Scholar
• Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. ASCUS-LSIL Triage Study (ALTS) Group. Am J Obstet Gynecol 2003;188:1383–1392.
   PubMedGoogle Scholar
• Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004;96:280–293.
   PubMed Web of Science ®Google Scholar
• Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol 2007;197:356.e1–6.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006;24:S3/78–89.
   Web of Science ®Google Scholar
• Ronco G, Cuzick J, Segnan N, Brezzi S, Carozzi F, Folicaldi S, et al.; NTCC working group. HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. Eur J Cancer 2007;43:476–480.
   PubMed Web of Science ®Google Scholar
• Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. J Natl Cancer Inst 2000;92:397–402.
   PubMedGoogle Scholar
• Castle PE, Fetterman B, Thomas Cox J, Shaber R, Poitras N, Lorey T, Kinney W. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer. Obstet Gynecol 2010;116:76–84.
   PubMed Web of Science ®Google Scholar
• Sherman ME, Castle PE, Solomon D. Cervical cytology of atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H): characteristics and histologic outcomes. Cancer 2006;108:298–305.
   PubMed Web of Science ®Google Scholar
• Castle PE, Fetterman B, Poitras N, Lorey T, Shaber R, Kinney W. Relationship of atypical glandular cell cytology, age, and human papillomavirus detection to cervical and endometrial cancer risks. Obstet Gynecol 2010;115:243–248.
   PubMed Web of Science ®Google Scholar
• Paraskevaidis E, Arbyn M, Sotiriadis A, Diakomanolis E, Martin-Hirsch P, Koliopoulos G, et al. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev 2004;30:205–211.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol 2005;99(3 Suppl 1):S7–S11.
   Web of Science ®Google Scholar
• Jones J, Saleem A, Rai N, Shylasree TS, Ashman S, Gregory K, et al. Human papillomavirus genotype testing combined with cytology as a ‘test of cure’ post treatment: The importance of a persistent viral infection. J Clin Virol 2011;52:88–92.
   PubMed Web of Science ®Google Scholar
• Kitchener HC, Walker PG, Nelson L, Hadwin R, Patnick J, Anthony GB, et al. HPV testing as an adjunct to cytology in the follow up of women treated for cervical intraepithelial neoplasia. BJOG 2008;115:1001–1007.
   PubMed Web of Science ®Google Scholar
• Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, et al.; VENICE 2 project gatekeepers group. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. Euro Surveill 2010;15:19730.
   Google Scholar
• European Medicines Agency. Cervarix human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed). Available at: http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000721/human_med_000694.jsp&mid=WC0b01ac058001d124. Accessed on 9 July 2012.
   Google Scholar
• European Medicines Agency. Gardasil human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed). Available at: http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000703/human_med_000805.jsp&mid=WC0b01ac058001d124. Accessed on 9 July 2012.
   Google Scholar
• Brotherton JM, Deeks SL, Campbell-Lloyd S, Misrachi A, Passaris I, Peterson K, et al. Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia. Commun Dis Intell 2008;32:457–61.
   Google Scholar
• Franco EL, Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 2008;26:A16–23.
   PubMed Web of Science ®Google Scholar
• Franceschi S, Denny L, Irwin KL, Jeronimo J, Lopalco PL, Monsonego J, et al. Eurogin 2010 roadmap on cervical cancer prevention. Int J Cancer 2011;128:2765–2774.
   PubMed Web of Science ®Google Scholar
• Mayrand MH, Franco EL. Integrating novel primary- and secondary-prevention strategies: the next challenge for cervical cancer control. Future Oncol 2010;6:1725–1733.
   PubMed Web of Science ®Google Scholar
• Drolet M, Brisson M, Maunsell E, Franco EL, Coutlée F, Ferenczy A, et al. The psychosocial impact of an abnormal cervical smear result. Psychooncology 2011 Jun 21. doi: 10.1002/pon.2003.
   PubMed Web of Science ®Google Scholar
• Wardle J, Waller J, Brunswick N, Jarvis MJ. Awareness of risk factors for cancer among British adults. Public Health 2001;115:173–174.
   PubMed Web of Science ®Google Scholar
• Waller J, McCaffery K, Forrest S, Szarewski A, Cadman L, Wardle J. Awareness of human papillomavirus among women attending a well woman clinic. Sex Transm Infect 2003;79:320–322.
   PubMed Web of Science ®Google Scholar
• Dell DL, Chen H, Ahmad F, Stewart DE. Knowledge about human papillomavirus among adolescents. Obstet Gynecol 2000;96:653–656.
   PubMed Web of Science ®Google Scholar
• Anhang R, Goodman A, Goldie SJ. HPV communication: review of existing research and recommendations for patient education. CA Cancer J Clin 2004;54:248–259.
   PubMed Web of Science ®Google Scholar